Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 7/20 | 0.32 |
| ▸ | VEGFA | P15692 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972842 | 1.00 | GPR119 (0.35) | GPR119EPAS1VEGFACYP11B2CYP11B1 | |
| SCHEMBL2142042 | 0.88 | XDH (0.43) | GPR119CYP11B2CYP11B1PIK3CG | |
| SCHEMBL2142044 | 0.88 | XDH (0.43) | GPR119CYP11B2CYP11B1PIK3CG | |
| SCHEMBL2140945 | 0.85 | CYP11B2 (0.36) | CYP11B2CYP11B1PIK3CG | |
| SCHEMBL2140938 | 0.85 | CYP11B2 (0.36) | CYP11B2CYP11B1PIK3CG | |
| SCHEMBL2137712 | 0.85 | CYP1A2 (0.32) | CYP11B2CYP11B1 | |
| SCHEMBL2137701 | 0.85 | CYP1A2 (0.32) | CYP11B2CYP11B1 | |
| SCHEMBL1974498 | 0.84 | ATM (0.31) | — | |
| SCHEMBL1974499 | 0.84 | ATM (0.31) | — | |
| SCHEMBL2140185 | 0.84 | CYP11B2 (0.35) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668021-B1 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | FOURNIER LAB SA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-7470671-B2 | Thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics | LABORATOIRE FOURNIER (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | NOTUM, STS, AGPS | GPR119 1416/4885EPAS1 1257/4885VEGFA 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.